A Food and Drug Administration panel opened a new era in medicine on Wednesday, unanimously recommending that the agency approve the first-ever treatment that genetically alters a patient’s own cells to fight cancer, transforming them into what scientists call “a living drug” that powerfully bolsters the immune system to shut down the disease.
{iframe}https://www.nytimes.com/2017/07/12/health/fda-novartis-leukemia-gene-medicine.html?emc=edit_na_20170712&nl=breaking-news&nlid=34889205&ref=cta{/iframe}